GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease

Department

Internal Medicine

Document Type

Article

Publication Title

Cardiovascular Drugs and Therapy

Abstract

Background: GLP1 receptor agonists (GLP-1 RAs) improve cardiorenal outcomes in chronic kidney disease (CKD) patients with obesity or type 2 diabetes. Whether GLP-1 RAs reduce risk of atrial fibrillation (AF) in CKD patients, especially in absence of diabetes or obesity, is unclear.

Objective: Investigate association between GLP-1 RA use and AF in patients with CKD.

Methods: Using the TriNetX US Collaborative Network, we identified patients with CKD without prior AF or kidney failure. First use of GLP-1 RA (exposure) served as index event. For non-users, an outpatient visit after chronic kidney disease diagnosis served as pseudo-index event. After 1:1 propensity score matching of users to non-users for baseline risk factors, the cohort was followed up from index/pseudo-index event up to 3 years, death, or end of study period. Primary outcome was incident AF; secondary outcomes were AF-related interventions (a composite of ablation therapy, left atrial appendage occlusion, cardioversion, or pacemaker implantation), heart failure exacerbation, use of antiarrhythmic therapy, major adverse cardiovascular events, kidney failure, major adverse kidney events, and death. Survival analyses were performed.

Results: After propensity score matching, each cohort-GLP-1 RA and non-GLP-1 RA-had 37,768 patients with CKD without prior AF or kidney failure. Mean age was 67 ± 11 years; 55% female; 21% Black; 63% diabetic; mean body mass index, 34 ± 7 kg/m2; and mean eGFR, 49 ± 20 mL/min/1.73 m². GLP-1 RA cohort developed fewer atrial fibrillation (6.9%) than non-GLP-1 RA cohort (12.4%) with HR 0.59, 95% CI 0.56-0.62. Associations remained consistent in non-obese (HR 0.63, 95% CI 0.57-0.70), non-diabetic (HR 0.42, 95% CI 0.36-0.49), and non-diabetic + non-obese (HR 0.59, 95% CI 0.46-0.77) subgroups. Use of GLP-1 RA was also associated with lower risk of composite AF-related interventions (HR 0.58, 95% CI 0.55-0.61), heart failure exacerbation (HR 0.48, 95% CI 0.46-0.49), antiarrhythmic therapy (HR 0.6, 95% CI 0.56-0.65), major adverse cardiovascular events (HR 0.58, 95% CI 0.56-0.59), progression to kidney failure (HR 0.70, 95% CI 0.66-0.74), major adverse kidney events (HR 0.55, 95% CI 0.53-0.56), and death (HR 0.52; 95% CI, 0.49-0.55).

Conclusion: In this retrospective cohort, use of GLP-1 RAs was associated with lower risk of AF in non-dialysis CKD patients, even those without diabetes or obesity.

First Page

2289

Last Page

2301

DOI

10.1007/s10557-026-07897-0

Volume

40

Issue

6

Publication Date

12-1-2026

Medical Subject Headings

Humans; Atrial Fibrillation; Female; Renal Insufficiency, Chronic; Male; Glucagon-Like Peptide-1 Receptor Agonists; Aged; Risk Factors; Middle Aged; United States; Incretins; Glucagon-Like Peptide-1 Receptor

PubMed ID

42397479

Share

COinS